May 25, 2024

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Classification of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd. (our wholly owned subsidiary) – Reg.,

Ref : Our letters dated February 02, 2024, February 29, 2024 and March 12, 2024

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) had conducted an inspection at Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Pashamylaram, Patancheru Mandal, Sangareddy District, Telangana, from 22nd January to 2nd February 2024.

Subsequently, the US FDA has determined the inspection classification status of this facility as 'Official Action Indicated (OAI)'.

The company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.

We will keep the stock exchanges informed about further developments.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

BADDIGAM ADI REDDY
Digitally signed by BADDIGAM ADI REDDY
Date: 2024.05.25 10:28:55 +05'30'

B. Adi Reddy
Company Secretary